The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 2024

Filed:

Sep. 22, 2020
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Jamie M. Orengo, Cortlandt Manor, NY (US);

Jeanne Allinne, Paris, FR;

Andrew J. Murphy, Croton-on-Hudson, NY (US);

George D. Yancopoulos, Yorktown Heights, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 14/715 (2006.01); A61P 37/00 (2006.01); A61P 17/06 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 37/08 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 1/04 (2006.01); A61P 9/14 (2006.01); A61P 11/02 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 38/1793 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 1/04 (2018.01); A61P 9/14 (2018.01); A61P 11/00 (2018.01); A61P 11/02 (2018.01); A61P 11/06 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 37/00 (2018.01); A61P 37/08 (2018.01); C07K 14/7155 (2013.01); C07K 16/244 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.


Find Patent Forward Citations

Loading…